Selected research
Industry Research
Duvelisib for Relapsed CLL/SLL Industry Research Report 2026
Market perspective
The global Duvelisib for Relapsed CLL/SLL market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Duvelisib for Relapsed CLL/SLL is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Duvelisib for Relapsed CLL/SLL is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Duvelisib for Relapsed CLL/SLL is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Duvelisib for Relapsed CLL/SLL include Secura Bio and CSPC among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Duvelisib for Relapsed CLL/SLL market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Duvelisib for Relapsed CLL/SLL Market by Company
Secura Bio
CSPC
Duvelisib for Relapsed CLL/SLL Segment by Type
25mg
15mg
Duvelisib for Relapsed CLL/SLL Segment by Application
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Duvelisib for Relapsed CLL/SLL Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duvelisib for Relapsed CLL/SLL market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Duvelisib for Relapsed CLL/SLL and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duvelisib for Relapsed CLL/SLL.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Duvelisib for Relapsed CLL/SLL manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Duvelisib for Relapsed CLL/SLL by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Duvelisib for Relapsed CLL/SLL in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25mg
- 15mg
Applications
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Companies covered
- Secura Bio
- CSPC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Duvelisib for Relapsed CLL/SLL Market Size (2021-2032)
- 2.2.2 Global Duvelisib for Relapsed CLL/SLL Sales (2021-2032)
- 2.2.3 Global Duvelisib for Relapsed CLL/SLL Market Average Price (2021-2032)
- 2.3 Duvelisib for Relapsed CLL/SLL by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25mg
- 2.3.3 15mg
- 2.4 Duvelisib for Relapsed CLL/SLL by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Chronic Lymphocytic Leukemia (CLL)
- 2.4.3 Small Lymphocytic Lymphoma (SLL)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Duvelisib for Relapsed CLL/SLL Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Duvelisib for Relapsed CLL/SLL Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Duvelisib for Relapsed CLL/SLL Revenue of Manufacturers (2021-2026)
- 3.4 Global Duvelisib for Relapsed CLL/SLL Average Price by Manufacturers (2021-2026)
- 3.5 Global Duvelisib for Relapsed CLL/SLL Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Duvelisib for Relapsed CLL/SLL, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Duvelisib for Relapsed CLL/SLL, Product Type & Application
- 3.8 Global Manufacturers of Duvelisib for Relapsed CLL/SLL, Established Date
- 3.9 Global Duvelisib for Relapsed CLL/SLL Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Secura Bio
- 4.1.1 Secura Bio Company Information
- 4.1.2 Secura Bio Business Overview
- 4.1.3 Secura Bio Duvelisib for Relapsed CLL/SLL Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Secura Bio Duvelisib for Relapsed CLL/SLL Product Portfolio
- 4.1.5 Secura Bio Recent Developments
- 4.2 CSPC
- 4.2.1 CSPC Company Information
- 4.2.2 CSPC Business Overview
- 4.2.3 CSPC Duvelisib for Relapsed CLL/SLL Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSPC Duvelisib for Relapsed CLL/SLL Product Portfolio
- 4.2.5 CSPC Recent Developments
5 Global Duvelisib for Relapsed CLL/SLL Market Scenario by Region
- 5.1 Global Duvelisib for Relapsed CLL/SLL Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021-2032
- 5.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2021-2026
- 5.2.2 Global Duvelisib for Relapsed CLL/SLL Sales by Region: 2027-2032
- 5.3 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021-2032
- 5.3.1 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2021-2026
- 5.3.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Region: 2027-2032
- 5.4 North America Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
- 5.4.1 North America Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 5.4.3 North America Duvelisib for Relapsed CLL/SLL Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
- 5.5.1 Europe Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 5.5.3 Europe Duvelisib for Relapsed CLL/SLL Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
- 5.6.1 Asia Pacific Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Duvelisib for Relapsed CLL/SLL Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
- 5.7.1 South America Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 5.7.3 South America Duvelisib for Relapsed CLL/SLL Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Duvelisib for Relapsed CLL/SLL Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Duvelisib for Relapsed CLL/SLL Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Duvelisib for Relapsed CLL/SLL Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Duvelisib for Relapsed CLL/SLL Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021-2032)
- 6.1.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Type (2021-2032)
- 6.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Type (2021-2032)
- 6.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Type (2021-2032)
- 6.3 Global Duvelisib for Relapsed CLL/SLL Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021-2032)
- 7.1.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Duvelisib for Relapsed CLL/SLL Sales Market Share by Application (2021-2032)
- 7.2 Global Duvelisib for Relapsed CLL/SLL Revenue by Application (2021-2032)
- 7.2.1 Global Duvelisib for Relapsed CLL/SLL Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Duvelisib for Relapsed CLL/SLL Revenue Market Share by Application (2021-2032)
- 7.3 Global Duvelisib for Relapsed CLL/SLL Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Duvelisib for Relapsed CLL/SLL Value Chain Analysis
- 8.1.1 Duvelisib for Relapsed CLL/SLL Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Duvelisib for Relapsed CLL/SLL Production Mode & Process
- 8.2 Duvelisib for Relapsed CLL/SLL Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Duvelisib for Relapsed CLL/SLL Distributors
- 8.2.3 Duvelisib for Relapsed CLL/SLL Customers
9 Global Duvelisib for Relapsed CLL/SLL Analyzing Market Dynamics
- 9.1 Duvelisib for Relapsed CLL/SLL Industry Trends
- 9.2 Duvelisib for Relapsed CLL/SLL Industry Drivers
- 9.3 Duvelisib for Relapsed CLL/SLL Industry Opportunities and Challenges
- 9.4 Duvelisib for Relapsed CLL/SLL Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst